Sign in
CompletedPhase 2

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants

Key facts

Who runs it
Shionogi
Where
Durham and Little Rock, United StatesSee the 2 sitesAlso in 2 other countries, 2 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
30 people enrolled
Started
14 Mar 2024
Ended
31 Mar 2025
Type of study
Interventional, 2 groups
Treatments tested
  • Cefiderocol
  • Standard of Care
Record updated
2 March 2026

Who can take part

Age
Up to 3 months
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who cannot take part

  • Urine output < 1.0 milliliter (mL)/kg/hour within the 24 hours prior to study drug administration on Day 1
  • Receiving renal replacement therapy
  • Received any other investigational medicinal product within 30 days of study drug administration
  • Receiving treatment with a vasopressor at Screening
  • Anticipated need for antibacterial therapy longer than 14 days (example , osteomyelitis or endocarditis); this applies to both study treatment with cefiderocol, as well as adjunctive IV antibacterial treatment for suspected coinfection with Gram-positive organisms or multidrug resistant Gram-negative organisms
  • Documented history of any moderate or severe hypersensitivity or allergic reaction to any β-lactam antibiotic
  • Any condition or circumstance that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data
  • Has a confirmed or strongly suspected infection at Screening with a pathogen known to be resistant to cefiderocol or only a Gram-positive pathogen or viral, fungal, or parasitic pathogen as the sole cause of infection
  • Suspected or confirmed central nervous system (CNS) infection, including suspected CNS infection who do not have a lumbar puncture (LP) but who are treated for potential CNS infection, evidence suggestive of CNS infection based on LP results (polymorphonuclear pleocytosis, hypoglycorrhachia, and increased protein concentration), regardless of culture results, LP with organisms on Gram stain or culture-positive cerebrospinal fluid; Note: Other protocol-defined Inclusion/Exclusion criteria may apply
  • Serum creatinine value greater than the maximum for GA and PNA shown below within the 24 hours prior to study drug administration on Day 1
  • Neonatal acute kidney injury (AKI), defined as a serum creatinine level greater than 1.5 milligrams per decilieter (mg/dL) (133 micromoles[μmol]/liter [L]) or an increase of 0.3 mg/dL (17 to 27 μmol/L) per day from a previous lower value
  • Acute kidney injury based on an increase in serum creatinine ≥ 0.3 mg/dL within 48 hours from an established baseline value
  • Life expectancy of < 72 hours after enrollment

Other criteria

  • Eligibility Criteria: Key Inclusion Criteria:
  • Written informed consent has been provided by parent(s) or legally authorized representative(s) in accordance with local regulatory requirements
  • Hospitalized infants from birth to < 3 months (< 90 days) of age at the time written informed consent is provided. Enrollment of premature infants will not be restricted, but they must have a GA ≥ 26 weeks, PNA of 0 to 3 months, and weight of at least 1 kilogram (kg)
  • Require systemic IV antibiotic treatment for suspected or confirmed aerobic Gram-negative infections including, but not limited to, complicated urinary tract infection, complicated intra-abdominal infection, hospital-acquired/ ventilator-associated bacterial pneumonia, and BSI/sepsis
  • For the multiple-dose phase, within 72 hours of the start of potentially effective treatment with SOC antibiotics for the suspected or confirmed primary aerobic Gram-negative infection

Where in United States

Also in 2 other countries, 2 sites

  • Duke UniversityDurham, United States
  • Arkansas Children's HospitalLittle Rock, United States

About the trial

What the trial wants to find out

The primary purpose of this study is to understand the pharmacokinetics (PK) of single and multiple doses of cefiderocol in children from birth to less than 3 months of age with suspected or confirmed aerobic Gram-negative bacterial infections.

The 2 groups in the trial

  • Single-Dose CefiderocolTreatment being tested

    Participants will receive a single dose cefiderocol on Day 1, along with standard of care antibiotics

    Treatment: Cefiderocol and Standard of Care

  • Multiple-Dose CefiderocolTreatment being tested

    Participants will receive cefiderocol every 8 hours for 5 to 14 days, along with standard of care antibiotics

    Treatment: Standard of Care

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Single-arm, Open-label Study to Assess the Pharmacokinetics, Safety, and Tolerability of Cefiderocol in Hospitalized Pediatric Patients From Birth to < 3 Months of Age With Suspected or Confirmed Aerobic Gram-negative Bacterial Infections
Record updated
2 March 2026